Phase III progression-free survival data were positive for first-line Braftovi i...
EyePoint has entered the final phase of development for its lead product, Duravy...
Alvotech and UK-based Advanz Pharma sign agreement to commercialise three additi...
Stealth Bio has cut 30% of its workforce as it eyes a resubmission based on disc...
Astellas Pharma has signed an exclusive licensing agreement with Evopoint Biosci...
Daiichi and MSD have voluntarily withdrawn the BLA in the US for their patrituma...
The EC has granted approval for the new subcutaneous (SC) formulation of Bristol...
Merck KGaA is filing for global regulatory approvals of pimicotinib after it met...
Scynexis has resumed dosing of its Brexafemme (ibrexafungerp) drug in a Phase II...
Daiichi and MSD have voluntarily withdrawn the BLA in the US for their patrituma...
The HSS has terminated a contract previously awarded to Moderna to help advance ...
Expanding the reach of CAR-T therapeutics could unlock promising new treatment p...
Telesis Bio has announced a licensing agreement with Regeneron, enabling the lat...
iTeos will look to distribute its cash reserves to shareholders, along with proc...
Eton Pharmaceuticals’ NDA for Khindivi, an oral solution of hydrocortisone, has ...
